Revelation Biosciences, INC DEF 14A proxy statements

Revelation Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 24, 2026, and is seeking stockholder approval for a reverse stock split to maintain Nasdaq listing compliance.

Revelation Biosciences, Inc. is holding a Special Meeting to seek stockholder approval for the issuance of common stock related to recent Class J Warrants, crucial for funding its lead product candidate, Gemini.

Revelation Biosciences, Inc. calls a Special Meeting to approve the issuance of common stock exceeding Nasdaq's 20% cap, crucial for funding and continued listing.

Revelation Biosciences, Inc. calls a Special Meeting to approve the issuance of common stock exceeding Nasdaq's 20% cap, crucial for funding operations and maintaining listing.

Revelation Biosciences, Inc. has announced its 2025 Annual Meeting of Stockholders, where key proposals include a potential reverse stock split, an amendment to its equity incentive plan, and approval for share issuance related to recent warrants, all while acknowledging substantial doubt about its ability to continue as a going concern.

Revelation Biosciences is reminding shareholders to vote in favor of Proposal 2 at the upcoming special meeting on January 17, 2025, which aims to redomicile the company to Nevada and save at least $200,000 annually in franchise tax fees.

Revelation Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on May 15, 2024, to vote on director elections, an equity incentive plan amendment, and auditor ratification.